Long-term study of postmenopausal women does not support many preventive therapies
May 02, 2024
Hormone therapy was no aid for cardiovascular disease prevention, and calcium/vitamin D supplementation was no aid for universal fracture prevention.
Social determinants of health tied to atherosclerotic CVD risk
May 01, 2024
The authors say that social determinants could increase the prediction ability of risk tools, particularly for Black patients.
More medical lab tests will soon face federal scrutiny, FDA says
Apr 29, 2024
Laboratory tests used by millions of Americans are soon to be classified as medical devices, and as such be regulated by the US Food and Drug Administration, the agency announced Monday.
Good heart health may protect against cognitive decline in black women
Apr 24, 2024
The finding was seen for processing speed and cardiovascular health in Black women but not white women.
AI may be useful in polypharmacy management
Apr 24, 2024
ChatGPT deprescribing decisions varied along activities of daily living status, cardiovascular disease history, and medication type
ACP: Recommendations developed for newer type 2 diabetes medications
Apr 22, 2024
A strong recommendation was given for the addition of an SGLT-2 or GLP-1 agonist to metformin, and lifestyle modifications.
Gains in heart health only experienced by higher-income populations
Apr 19, 2024
The 10-year risk for cardiovascular disease remained stagnant at >8% for US adults with the lowest incomes in 1988 to 2018.
Menopausal hormone therapy use beyond 65 years beneficial
Apr 16, 2024
Use of menopausal hormone therapy beyond age 65 years is associated with risk reductions in mortality as well as specific cancers and cardiovascular diseases, according to a study published online April...
Acute cardiac event reported in 22.4 percent of seniors hospitalized with RSV
Apr 15, 2024
Risk for experiencing acute cardiac event higher for adults with underlying cardiovascular disease
ACC: Gamification plus financial incentives boost physical activity
Apr 11, 2024
Greatest effect seen during both the 12-month intervention and at six-month follow-up among patients at high risk for cardiovascular events
